Table 1 Basic clinical characteristics of 86 patients with NMOSD

Female: male (ratio)

75:11(7:1)

Age, y, mean ± sd

46.2 ± 13.8

AQP4-IgG-positive, n (%)

74(86.0)

History of myelitis during the disease, n (%)

83(96.5)

EDSS, mean ± sd

4.3 ± 2.7

Length of spinal cord involvement, mean ± sd^a

4.4 ± 4.7

Attack type, n (%)

  Optic neuritis

27(31.4)

  Myelitis

63(73.3)

  Brain stem

17(19.8)

MR lesion type, n (%)^a

  Cervical

30(44.8)

  Thoracic

33(49.3)

  Lumber

2(3.0)

  Brain stem

18(26.9)

  Optic

8(11.9)

Isolated thoracic, n (%)^a

13(19.4)

Upper thoracic lesions, n (%)^a

27(40.3)

Lower thoracic lesions, n (%)^a

18(26.9)

≥ 4 thoracic lesions, n (%)^a

18(26.9)

≥ 3 spinal lesions, n (%)^a

40(59.7)

IVMP, n (%)

65(87.8)

Intravenous immunoglobulin, n (%)

16(21.6)

Plasma exchange, n (%)

2(2.7)

Oral glucocorticoid, n (%)

83(96.5)

AZA, n (%)

45(52.3)

MMF, n (%)

13(15.1)